gsd-review-backlog
Use when 999.x backlog items need triage, or the user asks to review, promote, or prune the backlog. Shows each item with its accumulated context, promotes chosen ones into the active milestone, and removes stale ones.
- License 许可
- Apache-2.0
- 最近更新
- 2026-11-11
- Stars
- ★ 631
- Forks
- 15
01 前言 Front Matter
- name
- gsd-review-backlog
- description
- Use when 999.x backlog items need triage, or the user asks to review, promote, or prune the backlog. Shows each item with its accumulated context, promotes chosen ones into the active milestone, and removes stale ones.
- allowed-tools
- [ "Read", "Write", "Bash", "AskUserQuestion" ]
03 SKILL.md 正文
<objective> Review all 999.x backlog items and optionally promote them into the active milestone sequence or remove stale entries. </objective>
<process>
-
List backlog items:
ls -d .planning/phases/999* 2>/dev/null || echo "No backlog items found" -
Read ROADMAP.md and extract all 999.x phase entries:
cat .planning/ROADMAP.mdShow each backlog item with its description, any accumulated context (CONTEXT.md, RESEARCH.md), and creation date.
-
Present the list to the user via AskUserQuestion:
- For each backlog item, show: phase number, description, accumulated artifacts
- Options per item: Promote (move to active), Keep (leave in backlog), Remove (delete)
-
For items to PROMOTE:
- Create the phase in the active milestone and capture its number (this creates the
.planning/phases/{NEW_NUM}-slugdirectory):NEW_NUM=$(node "$HOME/.claude/get-shit-done/bin/gsd-tools.cjs" phase add "${DESCRIPTION}" --raw) - Move the accumulated artifacts from
999.x-sluginto the new directory, then drop the now-empty backlog directory:mv ".planning/phases/999.x-slug/"* ".planning/phases/${NEW_NUM}-slug/" 2>/dev/null rmdir ".planning/phases/999.x-slug" 2>/dev/null - Update ROADMAP.md: move the entry from
## Backlogsection to the active phase list - Remove
(BACKLOG)marker - Add appropriate
**Depends on:**field
- Create the phase in the active milestone and capture its number (this creates the
-
For items to REMOVE:
- Confirm a second time before deleting, stating that this removes the phase directory
and its accumulated artifacts recursively:
rm -rf ".planning/phases/999.x-slug" - Remove the entry from ROADMAP.md
## Backlogsection
- Confirm a second time before deleting, stating that this removes the phase directory
and its accumulated artifacts recursively:
-
Commit changes:
node "$HOME/.claude/get-shit-done/bin/gsd-tools.cjs" commit "docs: review backlog — promoted N, removed M" --files .planning/ROADMAP.md -
Report summary:
## 📋 Backlog Review Complete Promoted: {list of promoted items with new phase numbers} Kept: {list of items remaining in backlog} Removed: {list of deleted items}
</process>
04 同仓库更多 Skills
trading-super-intelligence
Trading Super Intelligence Team. Named real-world personas across 8 cells. Built local-first (LM Studio) and validator-gated. Illustrative composites; see DISCLAIMER.md.
strategy-super-intelligence
Strategy Super Intelligence Team. Named real-world personas across 7 cells. Built local-first (LM Studio) and validator-gated. Illustrative composites; see DISCLAIMER.md.
risk-compliance-super-intelligence
Risk & Compliance (GRC) Super Intelligence Team. Named real-world personas across 7 cells. Built local-first (LM Studio) and validator-gated. Illustrative composites; see DISCLAIMER.md.
product-design-super-intelligence
Your product + design brain trust and decision partner. Named personas across 8 cells spanning product strategy, discovery/research, growth/metrics, design foundations/usability, design leadership/craft, UX/content, design systems, and a…
legal-ip-super-intelligence
Your legal, IP, and regulatory brain trust. 31 named personas across 7 cells covering patent strategy, tech licensing, regulatory litigation, AI governance, open-source compliance, privacy law, and antitrust.
healthcare-life-sciences-super-intelligence
Your healthcare and life sciences brain trust. 25 named personas across 7 cells covering drug discovery, medtech, biotech strategy, health policy, genomics, clinical trials, and healthcare economics.